Add your contracts into your own private organization for FREE

  • Upload contract files from your computer
  • Import contracts from Dropbox and Google Drive in bulk
  • Powerfull fulltext search across your contracts, clauses and categories
  • Automatic personalized clauses and categories library
  • Manage users within your organization to grant read or write access
  • SSL and at-rest encryption
  • Mobile access


The over 1,233,750 contracts contained on this website are SEC document filings that have been catalogued and indexed by contract type, state/jurisdiction, company, signees and filing date. Read more

Recently Added Contracts

Qtech Ltd. – Dated the 26th Day of February, 2018 Qtech Ltd. (As Company) AND the Core Trust Company Limited (As Trustee) AND Qu World Limited (As Nominee A) AND QFUN Limited (As Nominee B) TRUST DEED FOR CERTAIN EQUITY INCENTIVE SCHEMES OF QTECH LTD. (August 17th, 2018)
Durect Corporation – Fifth Amendment to Lease (August 17th, 2018)

This Fifth Amendment to Lease (this "Fifth Amendment") is made and entered into effective as of August 15, 2018, which is the date that this Fifth Amendment has been fully executed by all of those persons required to sign it (the "Effective Date"), by and between De Anza Enterprises LLC, a California limited liability company ("Landlord"), and DURECT Corporation, a Delaware corporation ("Tenant"), with respect to the following facts:

Amendment to the Rights Agreement (August 17th, 2018)
Entasis Therapeutics Ltd – Entasis Therapeutics Holdings Inc. Stock Incentive Plan Nonqualified Stock Option Agreement (August 17th, 2018)

THIS OPTION (the Option) is hereby granted as of [ ] (the Date of Grant) by Entasis Therapeutics Holdings Inc. (the Company) to [ ] (the Optionee) pursuant to the Entasis Therapeutics Holdings Inc. Amended and Restated Stock Incentive Plan (the Plan) and is subject to the terms and conditions set forth therein and as set out in this agreement (Award Agreement). Capitalized terms used herein shall, unless otherwise required by the context, have the meaning ascribed to such terms in the Plan.

Prothena Corporation Plc – MASTER COLLABORATION AGREEMENT by and Among PROTHENA BIOSCIENCES LIMITED and CELGENE SWITZERLAND LLC Dated as of March 20, 2018 (August 17th, 2018)
Strongbow Resources Inc. – Contract (August 17th, 2018)
Qtech Ltd. – Exclusive Technical and Consulting Service Agreement (August 17th, 2018)

THIS Exclusive Technical and Consulting Service Agreement (this Agreement) is made on October 13, 2017 by the following two parties in Shanghai, the Peoples Republic of China (PRC):

Variation of Terms of the Sale and Purchase Agreement (As Amended, Restated, Supplemented or Otherwise Modified From Time to Time, the Agreement) Dated 21 December 2017 Between (1) Quantum Strategic Partners Limited, Franek Sodzawiczny, Matthew Pullen, Louise Jarvis, Julian King, Nigel Rogers, Chester Reid, Michael Venables, Mark O'Keefe, Aslihan Gurescier, Keith Cronshaw, Pension Partnership SSAS Trustees Limited and Zenium Investorco Limited (Each a Seller and Together the Sellers), (2) Zenium Topco Limited, (3) CyrusOne Dutch Holdings B.V. (The Buyer), (4) ZTL Seller Rep, LLC and (5) CyrusO (August 17th, 2018)

This deed (this Ninth Side Letter) sets out the terms on which the Sellers' Representative (on behalf of the Sellers) and the Buyer have agreed to vary the terms of the Agreement, as varied in accordance with those certain Side Letters entered into between the Sellers' Representative (on behalf of the Sellers) and the Buyer on April 20, 2018, April 26, 2018, May 17, 2018, May 25, 2018, June 28, 2018, July 19, 2018, July 27, 2018 and August 10, 2018 (together, the Side Letters), in accordance with clause 20.5 of the Agreement. Unless otherwise defined in this Ninth Side Letter, the terms defined in the Agreement shall have the same meanings in this Ninth Side Letter.

Principia Biopharma Inc. – AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT for RSK Inhibitors and Novel Electrophiles (August 17th, 2018)

This amended and restated license agreement (Agreement) is made effective this 31st day of May, 2012 (Amendment Effective Date), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (The Regents) and acting through its Office of Technology Management, University of California San Francisco (UCSF), 185 Berry Street, Suite 4603, San Francisco, California 94107 and Principia Biopharma Inc., a Delaware corporation, having a principal place of business at 400 East Jamie Court, Suite 302, South San Francisco, California 94080 (Licensee).

Oroplata Resources, Inc. – Convertible Promissory Note (August 17th, 2018)

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

Spatializer Audio Laboratories – Warrant Agent Agreement (August 17th, 2018)

WARRANT AGENT AGREEMENT (this "Warrant Agreement") dated as of August 16, 2018 (the "Issuance Date") between Ameri Holdings, Inc., a Delaware corporation (the "Company"), and Corporate Stock Transfer, Inc. (the "Warrant Agent").

Entasis Therapeutics Ltd – Entasis Therapeutics Holdings Inc. 2018 Employee Stock Purchase Plan Adopted by the Board of Directors: , 2018 Approved by the Stockholders: , 2018 (August 17th, 2018)
Altair International Corp. – Contract (August 17th, 2018)
Altair International Corp. – Contract (August 17th, 2018)
Xg Sciences Inc – Code of Business Conduct and Ethics Effective August 14, 2018 (August 17th, 2018)

This Code of Business Conduct and Ethics (this "Code") has been adopted by the Board of Directors of XG Sciences, Inc., a Michigan corporation (the "Company," "we," "our" or "us"), to promote: a safe, diverse, and harassment-free workplace; honest and ethical conduct; appropriate external communications and responsible use of social media; full, fair, accurate, timely, and understandable disclosure in the periodic reports that we file with the Securities and Exchange Commission ("SEC"); and compliance with applicable laws, rules, and regulations ("Applicable Laws") by the Company's directors, officers and employees. This Code summarizes the legal, ethical and regulatory standards that the Company follows and applies to all of the Company's directors, officers and employees.


THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of August 17, 2018, by and among Avista Healthcare Public Acquisition Corp., a Cayman Islands exempted company (Parent), Avista Healthcare Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Parent (Merger Sub), and Organogenesis Inc., a Delaware corporation (the Company). Each of the Company, Parent and Merger Sub shall individually be referred to herein as a Party and, collectively, the Parties. The term Agreement as used herein refers to this Agreement and Plan of Merger, as the same may be amended from time to time, and all schedules, exhibits and annexes hereto (including the Company Disclosure Letter and the Parent Disclosure Letter, as defined herein). Defined terms used in this Agreement are listed alphabetically in Schedule A, together with the section and, if applicable, subsection in which the definition of each such term is located.

Banc of California, Inc. 2018 Omnibus Stock Incentive Plan Restricted Stock Agreement (August 17th, 2018)
Dividend Capital Diversified Property Fund Inc. – Amendment to Agreement (August 17th, 2018)

THIS AMENDMENT TO AGREEMENT (this Amendment) is dated to be effective for all purposes as of March 1, 2018 (the Effective Date) and is entered into by and between BC Exchange Manager LLC, a Delaware limited liability company (BC Manager) and BC Exchange Advisor LLC, a Delaware limited liability company (BC Advisor) with reference to the following facts:

Altair International Corp. – Contract (August 17th, 2018)
Heritage NOLA Bancorp, Inc. – Heritage Nola Bancorp, Inc. 2018 Equity Incentive Plan (August 17th, 2018)

This non-qualified stock option agreement ("Option" or "Agreement") is and will be subject in every respect to the provisions of the 2018 Equity Incentive Plan (the "Plan") of Heritage NOLA Bancorp, Inc. (the "Company") which are incorporated herein by reference and made a part hereof, subject to the provisions of this Agreement. A copy of the Plan has been provided or made available to each person granted a stock option pursuant to the Plan. The holder of this Option (the "Participant") hereby accepts this Option, subject to all the terms and provisions of the Plan and this Agreement, and agrees that all decisions under and interpretations of the Plan and this Agreement by the committee responsible for administering the Plan (the "Committee") will be final, binding and conclusive upon the Participant and the Participant's heirs, legal representatives, successors and permitted assigns. Except where the context otherwise requires, the term "Company" will include the parent and all pr

Bioplus Life Corp. – Subscription Agreement (August 17th, 2018)

The undersigned (the "Subscriber"), desires to become a holder of common shares (the "Shares") of Bioplus Life Corp., a corporation organized under the laws of the state of Nevada (the "Company"); one share of Common Stock has a par value $0.0001 per share. Accordingly, the Subscriber hereby agrees as follows:

Banc of California, Inc. 2018 Omnibus Stock Incentive Plan Nonqualified Option Agreement (For Non-Employee Directors) (August 17th, 2018)
Pure Bioscience – Consultant Agreement (August 17th, 2018)

This CONSULTING AGREEMENT (the "Agreement") is entered into effective as of August 13, 2018 (the "Effective Date"), by and between Pure Bioscience, Inc., a Delaware corporation (the "Company"), and Dave Pfanzelter (the "Consultant"). The Company and the Consultant are hereinafter collectively referred to as the "Parties", and individually referred to as a "Party".

Banc of California, Inc. 2018 Omnibus Stock Incentive Plan Incentive Stock Option Agreement (August 17th, 2018)
Entasis Therapeutics Ltd – Entasis Therapeutics Holdings Inc. Stock Option Grant Notice (2018 Equity Incentive Plan) (August 17th, 2018)

Entasis Therapeutics Holdings Inc. (the Company), pursuant to its 2018 Equity Incentive Plan (the Plan), hereby grants to Optionholder an option to purchase the number of shares of the Companys Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control.